DV
Dividend Vision

REPL — Replimune Group, Inc.

Replimune Group, Inc. (REPL)

Total return is -1.3% over the past 8.1 years, 214.8 points behind SPY at 213.5%. Its deepest 1-year drawdown was 84.2%.

Replimune Group, Inc. is a clinical-stage biotechnology company developing oncolytic immunotherapies designed to activate the immune system against cancer, with lead candidates RP1 (based on a modified herpes simplex virus) and RP2 (expressing an anti-CTLA-4 antibody-like protein) in development for solid tumors. The company does not currently distribute dividends. This security appeals primarily to growth-oriented investors with risk tolerance for early-stage biotech development, as the company remains in clinical stages without approved products or revenue.

REPL key facts

Asset type
Stock
Asset class
Equity
Inception date
07/20/2018
Distribution frequency
None
Last close
$14.97
Market cap
$1,403,101,568
Average volume
2398300.0
Beta
0.9
Payout ratio
0.0
Forward P/E
0.0
EPS
$-3.38